Розрахунок адекватності перитонеального діалізу — fractional urea clearance normalized to total body water, tracked across peritoneal and residual renal components
Kt/V is dialysis medicine's central adequacy metric: K (the clearance rate of a marker solute), multiplied by t (time), divided by V (the patient's volume of distribution — approximated by total body water). Because urea is small, freely diffusible, and easy to measure, it is used as the reference solute whose removal stands in for overall small-solute clearance achieved by a dialysis prescription.
Urea is the terminal nitrogenous waste product of protein catabolism. It distributes essentially evenly across total body water (intracellular + extracellular fluid) and crosses the peritoneal membrane by simple diffusion without active transport or significant protein binding — properties that make it mathematically tractable and clinically representative of small-solute clearance generally.
Raw clearance (K, in mL/min) is not by itself a meaningful adequacy number because a small patient and a large patient need different absolute clearances to achieve the same physiological effect. Normalizing by V — the volume the marker solute is distributed in — converts an absolute clearance into a fractional clearance: what proportion of the patient's total urea-containing water is effectively cleared each week. This fractional framing is what allows a single number, Kt/V, to be compared meaningfully across patients of different sizes and used as a treatment target.
V is not measured directly in routine practice; it is estimated from validated anthropometric equations (e.g., Watson formula) using height, weight, age, and sex, since total body water tracks closely with these variables in the absence of major fluid overload or wasting.
Kt/V is a fractional clearance, not an absolute one: a Kt/V of 1.7 per week means the equivalent of 1.7 times the patient's entire body water volume has been cleared of urea over that week — not that 1.7 liters were removed.
Kt/V captures small-solute clearance well, but dialysis adequacy is broader than urea removal alone: fluid balance, middle-molecule and protein-bound solute clearance, nutritional status, blood pressure control, and residual kidney function preservation all matter clinically. Kt/V nonetheless remains the standard quantitative benchmark because it is reproducible, well validated against outcomes in peritoneal dialysis populations, and straightforward to calculate from routine 24-hour collections.
Because Kt/V is additive across clearance sources (peritoneal and renal), it also provides a natural framework for tracking how a patient's overall adequacy shifts over time as residual kidney function declines — prompting timely prescription review rather than reactive adjustment only after symptoms appear.
Total weekly Kt/V is the sum of two physiologically distinct but mathematically additive components: Kt/V achieved through the peritoneal dialysis exchanges themselves, and Kt/V contributed by whatever native kidney function the patient still retains. Both count fully toward the adequacy target, which is why preserving residual renal function is a major clinical priority in peritoneal dialysis management.
Kt/V-PD (peritoneal component): calculated from the 24-hour dialysate effluent — the total volume drained multiplied by the dialysate urea concentration gives the mass of urea removed, which is converted into an effective clearance and normalized by V, then annualized to a weekly figure.
Kt/V-renal (residual component): for patients with measurable residual kidney function, a 24-hour urine collection provides urine volume and urine urea concentration, from which renal urea clearance is calculated. Because residual native kidney clearance is generally considered more efficient per unit than peritoneal clearance (the kidney clears both small and larger solutes, and maintains clearance of poorly-dialyzed uremic toxins), clinical guidelines have historically applied some weighting considerations — but the basic weekly Kt/V summation treats both as directly additive.
Total weekly Kt/V = Kt/V-PD + Kt/V-renal.
A patient with abundant residual function may need a comparatively modest peritoneal prescription to meet target; as residual function wanes over months to years, the peritoneal component must be increased to compensate and keep total Kt/V above threshold.
Residual renal function (RRF) contributes disproportionate clinical value beyond its numeric Kt/V contribution: it assists with fluid removal, potassium and phosphate homeostasis, and clearance of middle molecules and protein-bound uremic toxins that peritoneal dialysis clears poorly. Loss of RRF is independently associated with worse outcomes even when total Kt/V is numerically maintained by increasing the peritoneal component.
Strategies to slow RRF decline include avoiding nephrotoxic exposures (contrast agents, NSAIDs, aminoglycosides), using ACE inhibitors or ARBs when appropriate, maintaining adequate blood pressure control, and avoiding volume depletion. Because RRF typically declines gradually over time, adequacy calculations should be repeated periodically (commonly every 4–6 months, or after clinical changes) to catch the point where the peritoneal prescription needs adjustment before total Kt/V falls below target.
A patient losing residual renal function needs the peritoneal prescription increased to compensate — this is exactly why periodic Kt/V recalculation, not a one-time assessment, is central to long-term PD management.
The Kt/V calculation depends entirely on accurate 24-hour collections: the complete peritoneal dialysate effluent from every exchange in a 24-hour period, and — where residual renal function exists — a parallel complete 24-hour urine collection. Incomplete or mistimed collections are the most common source of error in adequacy testing, so patient education on collection technique is essential.
The patient (or caregiver) saves the entire drained dialysate from every exchange performed over a full 24-hour period, pooling it in a collection container. At the end of the period, the total volume is measured and recorded, and a well-mixed sample is sent to the laboratory for urea (and often creatinine) concentration measurement.
Accuracy depends on capturing every exchange without loss — a missed or partial drain understates total clearance and can make an adequate prescription appear falsely inadequate. Patients are typically instructed to perform their usual, unmodified exchange schedule during the collection day so that the result reflects real-world clearance rather than an atypical regimen.
For patients who still produce urine, a simultaneous 24-hour urine collection is obtained: all voided urine over the same 24-hour window is pooled, total volume measured, and urea concentration determined. Urine urea clearance is then calculated from volume × concentration, normalized, and expressed as a weekly Kt/V-renal contribution.
Once both the dialysate-derived Kt/V-PD and the urine-derived Kt/V-renal are available, they are summed to yield total weekly Kt/V, which is then compared against the target threshold to determine whether the current prescription is adequate or requires adjustment.
Patients with no residual urine output skip the urine collection — their total Kt/V is simply the peritoneal component alone, which raises the bar on the PD prescription needing to independently meet the full target.
Because collections are self-performed at home, clear patient instructions and confirmation that "usual day" exchanges were followed are as important to result validity as the laboratory measurement itself.
Once total weekly Kt/V is calculated, it is compared against a minimum target threshold that serves as the adequacy benchmark for the prescription. A commonly referenced illustrative target is a weekly Kt/V of approximately 1.7; results at or above this line are generally considered to indicate an adequate small-solute clearance prescription, while results below it prompt review and likely intensification.
A total weekly Kt/V at or above the target threshold suggests the current combination of peritoneal exchange schedule and residual renal function is removing small solutes at a rate historically associated with acceptable outcomes in peritoneal dialysis populations. A result below threshold does not necessarily mean the patient is symptomatic or in immediate danger — but it does flag that the numeric margin for adequate small-solute clearance is thin, and that the gap should be closed proactively rather than left to erode further as residual function declines.
The size of the shortfall matters for how the response is calibrated: a result only marginally below target may warrant a modest volume increase, while a substantially low result — especially in a patient who has already lost most residual renal function — points toward a more significant prescription overhaul.
In practice, adequacy targets have evolved over time in the nephrology literature and are informed by considerations such as peritoneal membrane transport characteristics, whether residual renal function is present, and individual patient factors like nutritional status and symptom burden. The single illustrative threshold used here is a simplification for teaching and calculator purposes — real prescriptions are individualized, and a patient trending toward the threshold from above (declining residual function) warrants earlier proactive intervention than a stable patient sitting just below it with abundant residual clearance still contributing.
Being below the target line is a prompt for clinical review and shared decision-making about intensification — not an automatic, mechanical instruction to escalate therapy regardless of context.
When calculated Kt/V falls below the target threshold, several prescription-adjustment options are available, and the most appropriate choice depends on the size of the shortfall, the patient's peritoneal transport type, and how much residual renal function remains. Options range from simple volume changes to a more fundamental reconsideration of dialysis modality.
The most direct way to raise Kt/V-PD is to increase the volume of dialysate instilled per exchange (fill volume), which increases the surface area contact and total urea mass removed per cycle within tolerability limits. Alternatively, adding an additional exchange within the 24-hour cycle increases total dwell time and drainage volume across the day, raising cumulative clearance.
Both approaches are relatively straightforward prescription changes that can be implemented without a modality change, and are typically the first options considered for a modest shortfall against target.
Peritoneal Equilibration Test (PET) results classify a patient's peritoneal membrane transport characteristics — broadly from low to high transporter. This classification informs how dwell time and exchange frequency should be tuned: high transporters equilibrate solutes quickly and tend to benefit from shorter, more frequent dwells, while low transporters need longer dwell times to achieve equivalent clearance. Prescription adjustments made without accounting for transport type can be less effective or counterproductive.
When volume and exchange adjustments are insufficient — particularly once residual renal function has substantially declined and the peritoneal component alone must carry the full adequacy burden — a more fundamental review is warranted, including consideration of a modality change (for example, transitioning components of the regimen or to hemodialysis) to achieve reliable target clearance going forward.
Prescription adjustment is individualized: the same numeric Kt/V shortfall can call for a small volume tweak in one patient and a full modality reassessment in another, depending on transport type and remaining residual renal function.